Intervertebral Disc Regeneration by Autologous Stem Cell Transplantation

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514475-17-00

Enrollment

Registered

2024-10-15

Start date

2022-11-15

Completion date

Unknown

Last updated

2025-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

degenerative disc disease

Brief summary

Treatment success, pain reduction compared to control group Timeframe 2 yr, no post-intervention on treated level. No unexpected events by procedure., VAS-score, pain diary, EQ-5D, ODI, SF-36, LBPRS

Detailed description

MR morphology of disc: height, water content, fat and lipid, lactose, glucose, proteoglycans, collagen.

Interventions

DRUGMSC

DRUGadipose tissue

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Treatment success, pain reduction compared to control group Timeframe 2 yr, no post-intervention on treated level. No unexpected events by procedure., VAS-score, pain diary, EQ-5D, ODI, SF-36, LBPRS	—

Secondary

Measure	Time frame
MR morphology of disc: height, water content, fat and lipid, lactose, glucose, proteoglycans, collagen.	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026